المؤلفون: M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, A. Krishnan

المصدر: HemaSphere, Vol 6, Pp 789-790 (2022)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000846464.96684.8e; https://doaj.org/toc/2572-9241

URL الوصول: https://doaj.org/article/da56aab3fd274bec976461f733ba191f

المؤلفون: L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, P. Moreau

المصدر: HemaSphere, Vol 6, Pp 1885-1886 (2022)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000850888.63074.41; https://doaj.org/toc/2572-9241

URL الوصول: https://doaj.org/article/d0cf49676a7a41ebae93379be092b50d

المؤلفون: S. Chowdhury, S. Oudard, H. Uemura, S. Joniau, L. Dearden, C. Capone, S. van Sanden, J. Diels, B. A. Hadaschik, B. А. Hadaschik

المساهمون: Данное исследование и публикация статьи (сборы за быстрое рассмотрение и размещение статьи в открытом доступе) выполнены при финансовой поддержке компании Janssen Scientific Affairs, LLC

المصدر: Cancer Urology; Том 18, № 1 (2022); 77-89 ; Онкоурология; Том 18, № 1 (2022); 77-89 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: онкология, апалутамид, даролутамид, неметастатический кастрационнорезистентный рак предстательной железы

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1577/1361; Mohler J.L., Antonarakis E.S., Armstrong A.J. et al. Prostate cancer, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2019;17(5):479–505. DOI:10.6004/jnccn.2019.0023.; Dai C., Heemers H., Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med 2017;7(9):a030452. DOI:10.1101/cshperspect.a030452.; Howard L.E., Moreira D.M., De Hoedt A. et al. Thresholds for PSA doubling time in men with non-metastatic castrationresistant prostate cancer. BJU Int 2017;120(5B):E80–6. DOI:10.1111/bju.13856.; El-Amm J., Aragon-Ching J.B. The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin Med Insights Oncol 2019;13:1179554919833927. DOI:10.1177/1179554919833927.; Gillessen S., Attard G., Beer T.M. et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 2020;77(4):508–47. DOI:10.1016/j.eururo.2020.01.012.; Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. DOI:10.1056/NEJMoa1715546.; Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–46. DOI:10.1056/NEJMoa1815671.; Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465–74. DOI:10.1056/NEJMoa1800536.; Small E.J., Saad F., Chowdhury S. et al. Apalutamide and overall survival in nonmetastatic castration-resistant prostate cancer. Ann Oncol 2019;30(11):1813–20. DOI:10.1093/annonc/mdz397.; Smith M.R., Saad F., Chowdhury S. et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79(1):150–8. DOI:10.1016/j.eururo.2020.08.011.; Fizazi K., Shore N., Tammela T.L. et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383(11):1040–9. DOI:10.1056/NEJMoa2001342.; Phillippo D.A.T., Dias S., Palmer S. et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). 2016; 24 Jul 2020. Available at: http://www.nicedsu.org.uk/Populationadjusted-ICs-TSD(3026862).htm.; Signorovitch J.E., Sikirica V., Haim Erder M. et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 2012;15(6):940–7. DOI:10.1016/j.jval.2012.05.004.; Chowdhury S., Oudard S., Uemura H. et al. Matching-adjusted indirect comparison of the efficacy of apalutamide and enzalutamide with ADT in the treatment of nonmetastatic castration-resistant prostate cancer. Adv Ther 2020;37(1):501–11. DOI:10.1007/s12325-019-01156-5.; Chowdhury S., Oudard S., Uemura H. et al. Matching-adjusted indirect comparison of health-related quality of life and adverse events of apalutamide versus enzalutamide in non-metastatic castration-resistant prostate cancer. Adv Ther 2020;37(1):512–26. DOI:10.1007/s12325-019-01157-4.; Dias S., Sutton A.J., Ades A.E., Welton N.J. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33(5):607–17. DOI:10.1177/0272989X12458724.; National Institute for Health and Care Excellence, Technology Appraisal Guidance. 2017. Available at: https://www.nice.org.uk/about/what-wedo/our-programmes/niceguidance/nicetechnology-appraisal-guidance.; Phillippo D.M. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016. Available at: http://www.nicedsu.org.uk.; Glen S. Effective Sample Size: Definition, Examples. 2016 (17.12.2020). Available at: https://www.statisticshowto.com/effectivesample-size/.; Di Nunno V., Mollica V., Santoni M. et al. New hormonal agents in patients with non-metastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin Genitourin Cancer 2019;17(5):e871–7. DOI:10.1016/j.clgc.2019.07.001.; Liu Z., Zhang T., Ma Z. et al. Systemic management for nonmetastatic castrationresistant prostate cancer: a systematic review and network meta-analysis. Am J Clin Oncol 2020;43(4):288–97. DOI:10.1097/COC.0000000000000660.; Kumar J., Jazayeri S.B., Gautam S. et al. Comparative efficacy of enzalutamide, apalutamide and darolutamide for treatment on non-metastatic castrate-resistant prostate cancer: a network meta-analysis. J Urol 2020;203(Suppl 4):e1217(Abstract).; Cusano E., Boyne D.J., Lee-Ying R.M., Brenner D.R. Systemic therapy for nonmetastatic castrate-resistant prostate cancer (M0 CRPC): a systematic review and network meta-analysis (NMA). J Clin Oncol 2020;38(6 suppl):113. DOI:10.1200/JCO.2020.38.6_suppl.113.; Hird A.E., Bhindi B., Magee D.E., Ye X.Y. Novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer: a network meta-analysis. J Clin Oncol 2020;38(6):131. DOI:10.1200/JCO.2020.38.6_suppl.131.; Riaz I.B., Asghar N., Lang D.K. et al. A systematic review and network metaanalysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC). J Clin Oncol 2020;38(6):335. DOI:10.1200/jco.2020.38.6_suppl.335.; Altavilla A., Di Maio M., Tucci M. et al. Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT). Ann Oncol 2019;30(Suppl 5):339. DOI:10.1093/annonc/mdz248.025.; Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683–91. DOI:10.1016/s0895-4356(97)00049-8.; Nieto-Gómez P., Ubago-Pérez R., Cabeza-Barrera J. Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: indirect comparison. Actas Urol Esp 2019;43(7):355–63. DOI:10.1016/j.acuro.2019.03.007.; Wallis C.J.D., Chandrasekar T., Goldberg H. et al. Advanced androgen blockage in nonmetastatic castration-resistant prostate cancer: an indirect comparison of apalutamide and enzalutamide. Eur Urol Oncol 2018;1(3):238–41. DOI:10.1016/j.euo.2018.04.004.; Mills E.J., Ghement I., O’Regan C., Thorlund K. Estimating the power of indirect comparisons: a simulation study. PLoS One 2011;6(1):16237. DOI:10.1371/journal.pone.0016237.; Jansen J.P., Fleurence R., Devine B. et al. Interpreting indirect treatment comparisons and network meta-analysis for healthcare decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14(4):417–28. DOI:10.1016/j.jval.2011.04.002.; Drago J.Z., Kantoff P.W., Stopsack K.H. Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: how confident are we about which drug is safest? J Clin Oncol 2020;38(6 suppl):318.; https://oncourology.abvpress.ru/oncur/article/view/1577

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1577
https://doi.org/10.17650/1726-9776-2022-18-1-77-89

المؤلفون: S Van Sanden, N Rahhali, C Schioppa, J Diels, B Rodrigues, C Chandler, V Kapetanakis, R Jain, T Li

المصدر: Value in Health. 25:S526

مصطلحات موضوعية: Health Policy, Public Health, Environmental and Occupational Health

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d8fa509b5ea06f397549666c94b8ec66
https://doi.org/10.1016/j.jval.2022.04.1248

المؤلفون: B. Rive, J. Lundberg, M. Själin, C. Björkholm, A. Leval, S. Van Sanden, C. Hellner, A. Gannedahl, T. Cars

المصدر: European Neuropsychopharmacology. 40:S149-S150

مصطلحات موضوعية: Pharmacology, medicine.medical_specialty, business.industry, medicine.disease, Outcome (game theory), Indirect comparison, Clinical trial, Clinical Practice, Psychiatry and Mental health, Neurology, Internal medicine, medicine, Pharmacology (medical), Neurology (clinical), business, Treatment-resistant depression, Biological Psychiatry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8bbe72d4d614b0e45e104d12b2f21442
https://doi.org/10.1016/j.euroneuro.2020.09.197

المؤلفون: T. Disher, W. Noel, S. Van Sanden, Chetan S Karyekar, H. Fareen, I.B. McInnes, K. Eaton, P. J. Mease, W. H. Boehncke, A. Schubert, Christopher T. Ritchlin, S. Peterson

المصدر: Annals of the Rheumatic Diseases. 79:1713-1714

مصطلحات موضوعية: medicine.medical_specialty, Placebo response, business.industry, Immunology, Physical function, medicine.disease, General Biochemistry, Genetics and Molecular Biology, law.invention, Psoriatic arthritis, Systematic review, Guselkumab, Rheumatology, Randomized controlled trial, law, Internal medicine, Meta-analysis, medicine, Immunology and Allergy, In patient, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::de8a0d78b1adacf17ca302f0fcd85450
https://doi.org/10.1136/annrheumdis-2020-eular.6013

المؤلفون: S. van Sanden, A. Schubert, Joris Diels, J. Barthelmes

المصدر: Value in Health. 23:S410

مصطلحات موضوعية: Plaque psoriasis, Moderate to severe, Matching (statistics), medicine.medical_specialty, Guselkumab, business.industry, Health Policy, Tildrakizumab, Public Health, Environmental and Occupational Health, medicine, business, Dermatology, Indirect comparison

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::afe5cd1dd326ae27caca36d144fb3d44
https://doi.org/10.1016/j.jval.2020.08.081

المؤلفون: J Diels, N Rahhali, D Seshagiri, Arlene O. Siefker-Radtke, B Kowalski, Y Loriot, S Fleming, P De Porre, S Van Sanden

المصدر: Annals of Oncology. 30:v371-v372

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Vinflunine, business.industry, Phases of clinical research, Hematology, Indirect comparison, chemistry.chemical_compound, Docetaxel, chemistry, Erdafitinib, Atezolizumab, Internal medicine, medicine, Clinical endpoint, Progression-free survival, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d41b6f82ac4186c7ebae090d8cb2f5fc
https://doi.org/10.1093/annonc/mdz249.025

المؤلفون: P. De Porre, Seye Abogunrin, Susan Feyerabend, Maria Koufopoulou, F. Saad, Joris Diels, J. Roiz, S. Van Sanden, K. Fizazi, Tetsuro Ito

المصدر: European Urology Supplements. 18:e1395-e1396

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Urology, Abiraterone acetate, chemistry.chemical_compound, Hormone sensitive prostate cancer, chemistry, Docetaxel, Prednisone, Meta-analysis, Internal medicine, Overall survival, medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4c9d0527b328877075facd94f0115636
https://doi.org/10.1016/s1569-9056(19)31009-7

المؤلفون: S. van Sanden, Hirotsugu Uemura, Ajay S. Behl, Dominic Pilon, Joris Diels, Boris Hadaschik, Steven Joniau, Jinan Liu, Jan Sermon, L. Dearden, Stéphane Oudard, Martin Ladouceur, Simon Chowdhury

المصدر: Value in Health. 21:S20-S21

مصطلحات موضوعية: Oncology, 030213 general clinical medicine, Matching (statistics), medicine.medical_specialty, business.industry, Health Policy, Apalutamide, Public Health, Environmental and Occupational Health, Castration resistant, medicine.disease, Indirect comparison, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Internal medicine, medicine, Enzalutamide, Non metastatic, business, 030217 neurology & neurosurgery

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::43eba8a5127c658720c53431adc26e64
https://doi.org/10.1016/j.jval.2018.09.119

المؤلفون: S. van Sanden, Jan Sermon, Stéphane Oudard, Boris Hadaschik, L. Dearden, Hirotsugu Uemura, Jinan Liu, Steven Joniau, Simon Chowdhury, Joris Diels

المصدر: Value in Health. 22:S407

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Matching (statistics), business.industry, Health Policy, Apalutamide, Public Health, Environmental and Occupational Health, Castration resistant, medicine.disease, Indirect comparison, chemistry.chemical_compound, Prostate cancer, Darolutamide, Tolerability, chemistry, Internal medicine, Medicine, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e6bec01026b6d26f6e891edb88b3ff53
https://doi.org/10.1016/j.jval.2019.09.056

المؤلفون: Joris Diels, U. Siebert, S. van Sanden, Jan Sermon, Nolen J. Perualila

المصدر: Value in Health. 22:S103

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Health Policy, Apalutamide, Public Health, Environmental and Occupational Health, Castration resistant, medicine.disease, Androgen deprivation therapy, Prostate cancer, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Non metastatic, In patient, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::6d8cdf012c2b4b3c00165aece4880151
https://doi.org/10.1016/j.jval.2019.04.369

المؤلفون: O. Chirita, M. Van Agthoven, Johan Liwing, S. van Sanden, P. Thilakarathne, Joris Diels, Hareth Nahi

المصدر: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)

مصطلحات موضوعية: medicine.medical_specialty, Novel agents, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, Physical therapy, Intensive care medicine, business, medicine.disease, Multiple myeloma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc0636016c2101d7decef148bbcd51a
https://pubmed.ncbi.nlm.nih.gov/27201764

المؤلفون: Feng Pan, S. Van Sanden, Sonja Sorensen, S. Sun, Siyang Peng, Nishan Sengupta, Emily Dorman, M. Gaudig

المصدر: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)

مصطلحات موضوعية: chemistry.chemical_compound, chemistry, business.industry, Ibrutinib, Health Policy, Refractory Mantle Cell Lymphoma, Cancer research, Public Health, Environmental and Occupational Health, Medicine, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c06a7531dfe3beba139fd56d93c7e5
https://pubmed.ncbi.nlm.nih.gov/27202180

المؤلفون: Guillaume Ploussard, Redas Trepiakas, A. Reid, Dominique Beal-Ardisson, Louis-Marie Dourthe, L. Dearden, Antoine Thiery-Vuillemin, Elias Pintus, Mads Hvid Poulsen, Edouard Lagneau, S. Van Sanden, A. Birtle, M Lukac

المصدر: Annals of Oncology. 28:v287-v288

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Abiraterone acetate, Hematology, Castration resistant, medicine.disease, Surgery, chemistry.chemical_compound, Prostate cancer, chemistry, Prednisone, Internal medicine, medicine, Enzalutamide, Observational study, Multi centre, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::47b4c648873ac6242b4874e294505bab
https://doi.org/10.1093/annonc/mdx370.046

المؤلفون: N. Trevor, S. van Sanden, J. Anjo, H Pei, Nolen J. Perualila, Joris Diels

المصدر: Value in Health. 21:S400

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Second line, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Overall survival, Subgroup analysis, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3e06b4456f19c146f9406ab8381fbef1
https://doi.org/10.1016/j.jval.2018.09.2373

المؤلفون: Joris Diels, S. van Sanden

المصدر: Value in Health. 18(7)

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Relative efficacy, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Bayesian network, Ofatumumab, chemistry.chemical_compound, chemistry, Meta-analysis, Ibrutinib, Internal medicine, Relapsed refractory, medicine, business, Idelalisib

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ea3989b20746c00ce69353e9b4ff1d

المؤلفون: P. Guillon, AT Nielsen, S. Van Sanden, Joris Diels

المصدر: Value in Health. 18(3)

مصطلحات موضوعية: Canagliflozin, medicine.medical_specialty, Relative efficacy, business.industry, Glp 1 agonist, Health Policy, Public Health, Environmental and Occupational Health, Type 2 Diabetes Mellitus, Glucagon-like peptide-1, Endocrinology, Internal medicine, Meta-analysis, Medicine, In patient, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f0d509fbca1b0209c1e3d8cfe6d1d9f

المؤلفون: Martin Vogel, Tetsuro Ito, Joris Diels, S. Van Sanden

المصدر: Value in Health. 19:A713-A714

مصطلحات موضوعية: Oncology, Matching (statistics), medicine.medical_specialty, business.industry, Health Policy, Low dose, Public Health, Environmental and Occupational Health, Daratumumab, 030204 cardiovascular system & hematology, Pomalidomide, medicine.disease, Surgery, Indirect comparison, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, 030212 general & internal medicine, business, Multiple myeloma, Dexamethasone, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4cf8f5e1ba49a388f57360f3b69222c9
https://doi.org/10.1016/j.jval.2016.09.2103

المؤلفون: Tetsuro Ito, Fred Saad, P. De Porre, Seye Abogunrin, S. Van Sanden, Susan Feyerabend, J. Roiz, Tracy Li, Joris Diels, Karim Fizazi

المصدر: Annals of Oncology. 28:v277

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, 030232 urology & nephrology, Abiraterone acetate, Hematology, 03 medical and health sciences, chemistry.chemical_compound, Hormone sensitive prostate cancer, 0302 clinical medicine, chemistry, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::357700a9e17babe9acbb856bf05d1c57
https://doi.org/10.1093/annonc/mdx370.020